JIUNN-LEE LINWu, Tsu-JueyTsu-JueyWuChen, Ching-PeiChing-PeiChenHsu, Jung-ChengJung-ChengHsuUeng, Kwo-ChangKwo-ChangUengKuo, Jen-YuanJen-YuanKuoChen, Mien-ChengMien-ChengChenYeh, Kuan-HungKuan-HungYehChang, Kuan-ChengKuan-ChengChangLu, Yen-YuYen-YuLuShyu, Kou-GiKou-GiShyuWen, Ming-ShienMing-ShienWenChen, Shih-AnnShih-AnnChenHsieh, Ming-HsiungMing-HsiungHsiehTseng, Wei-KungWei-KungTsengFeng, An-NingAn-NingFengYang, Teng-YaoTeng-YaoYangKo, Wen-ChinWen-ChinKoCheng, Chi-WenChi-WenChengLiu, Ju-ChiJu-ChiLiuLai, Wen-TerWen-TerLai2023-09-072023-09-072020-010929-6646https://www.scopus.com/record/display.uri?eid=2-s2.0-85064516545&doi=10.1016%2fj.jfma.2019.03.009&origin=inward&txGid=40581d42075997a77608b392b8217a30https://scholars.lib.ntu.edu.tw/handle/123456789/635155Currently, data on the real-world use of dronedarone, an antiarrhythmic drug for atrial fibrillation (AF), are contradictory and often based on patient populations comprised of Caucasians. We prospectively investigated the efficacy and safety of dronedarone and risk factors related to treatment outcomes in a real-world use setting.enAtrial fibrillation; Dronedarone; Observational; Quality of life; Safetyjournal article10.1016/j.jfma.2019.03.009310235062-s2.0-85064516545